Zelboraf (Vemurafenib) is used to treat metastatic melanoma (skin cancer). Zelboraf (Vemurafenib) is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Zelboraf (Vemurafenib) is used only if your tumor has a specific genetic marker that your doctor will test for.
Zelboraf (Vemurafenib) is an orally available inhibitor of mutated BRAF-serine-threonine kinase. It is especially potent against the BRAF V600E mutation. This mutation involves the substitution of glutamic acid for valine at codon 600. The BRAF oncogene, most of which have the V600E mutation, activates mitogen-activated kinase (MAPK) pathway which results in cell growth, proliferation, and metastasis. Zelboraf (Vemurafenib) blocks these downstream processes to inhibit tumour growth and eventually trigger apoptosis. Zelboraf (Vemurafenib) does not have antitumour effects against melanoma cell lines with the wild-type BRAF mutation.
Hair loss, dry skin, headache, nausea, vomiting, diarrhea, swelling of ankles/feet/hands, or joint/muscle pain may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.
Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.
Store at room temperature away from moisture and heat. Keep the bottle tightly closed when not in use.
Before taking Zelboraf (Vemurafenib), tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.
Before using this medication, tell your doctor or pharmacist your medical history, especially of: radiation therapy.
Zelboraf (Vemurafenib) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.